Conference Correspondent

Data from the SPARK Study: Mutational Analysis of Patients with Primary Resistance to Ibrutinib in Relapsed/Refractory Mantle-Cell Lymphoma

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent — January 9, 2015

International Research Agenda for Multicentric Castleman’s Disease

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent — January 9, 2015

Updates on Treatments for Castleman’s Disease

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent — January 9, 2015

Pathology and Diagnosis of Multicentric Castleman’s Disease

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent — January 9, 2015

The Clinical Features of Multicentric Castleman's Disease

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent — January 9, 2015

Multicentric Castleman’s Disease Overview and Update on Its Pathogenesis

ASH 2014 - Castleman's Disease, ASH Highlights

Conference Correspondent — January 9, 2015

Enzalutamide Long-Term Safety and Efficacy in Hormone-Naïve Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent — September 30, 2014

Maximal Androgen Depletion with Abiraterone Acetate Followed by Molecular-Targeted Therapies in Metastatic Prostate Cancer: Finding an Androgen-Signaling Signature to Predict Response

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent — September 30, 2014

Chemohormonal Therapy versus Hormonal Therapy Alone in Men with Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent — September 30, 2014

AR-V7 Splice Variant as Prognostic Marker for Resistance to Enzalutamide or Abiraterone in Men with Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent — September 30, 2014

Page 35 of 44

32
33
34
35
36
37
38